Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1522282 (
EMT
)
2,868
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Advanced age portends a poorer prognosis in
FSGS
. To understand the impact of age on glomerular podocytes and parietal epithelial cells (PECs), experimental
FSGS
was induced in 3m-old mice (20-year old human age) and 27m-old mice (78-year old human age) by abruptly depleting podocytes with a cytopathic anti-podocyte antibody. Despite similar binding of the disease-inducing antibody, podocyte density was lower in aged
FSGS
mice compared to young
FSGS
mice. Activated PEC density was higher in aged versus young
FSGS
mice, as was the percentage of total activated PECs. Additionally, the percentage of glomeruli containing PECs with evidence of phosphorylated ERK and
EMT
was higher in aged
FSGS
mice. Extracellular matrix, measured by collagen IV and silver staining, was higher in aged
FSGS
mice along Bowman's capsule. However, collagen IV accumulation in the glomerular tufts alone and in glomeruli with both tuft and Bowman's capsule accumulation were similar in young
FSGS
and aged
FSGS
mice. Thus, the major difference in collagen IV staining in
FSGS
was along Bowman's capsule in aged mice. The significant differences in podocytes, PECs and extracellular matrix accumulation between young mice and old mice with
FSGS
might explain the differences in outcomes in
FSGS
based on age.
...
PMID:Compound effects of aging and experimental FSGS on glomerular epithelial cells. 2822 42